Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
MIBG With Dinutuximab +/- Vorinostat
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-11-18
- Target Recruit Count
- 45
- Registration Number
- NCT03332667
- Locations
- 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyDrug: CarboplatinDrug: BusulfanDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideDrug: Dexrazoxane HydrochlorideBiological: DinutuximabDrug: Doxorubicin HydrochlorideProcedure: EchocardiographyDrug: Etoposide PhosphateRadiation: External Beam Radiation TherapyRadiation: Iobenguane I-123Drug: IsotretinoinRadiation: Iobenguane I-131Procedure: Multigated Acquisition ScanDrug: LorlatinibDrug: Melphalan HydrochlorideProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingBiological: SargramostimProcedure: Therapeutic Conventional SurgeryDrug: ThiotepaDrug: Topotecan HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 724
- Registration Number
- NCT03126916
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Sargramostim for Myeloid Dendritic Cell Deficiency
- Conditions
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 4
- Registration Number
- NCT03063242
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 10
- Registration Number
- NCT03006146
- Locations
- 🇺🇸
University of California, Los Angeles, Los Altos, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Gliknik Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02873819
- Locations
- 🇭🇺
Bacs-Kiskun County Teaching Hospital, Kecskemét, Hungary
🇭🇺Medical Center of the University of Pecs, Pecs, Hungary
🇺🇦Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine
SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT02840708
- Locations
- 🇯🇵
Niigata University Med & Dental Hospital, Niigata, Japan
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT02835742
- Locations
- 🇯🇵
Niigata University Med & Dental Hospital, Niigata, Japan
High-Risk Neuroblastoma Chemotherapy Without G-CSF
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT02786719
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT02780401
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Pembrolizumab and GM-CSF in Biliary Cancer
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Robin Kate Kelley
- Target Recruit Count
- 42
- Registration Number
- NCT02703714
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.